Unimedic Pharma acquires XGX Pharma
-
Melatonin Unimedic Pharma 1 mg/ml drink for children with ADHD and insomnia now available in the Belgian market
Unimedic Pharma AB, in partnership with its distributor TwinPharma BV, has launched Melatonin Unimedic Pharma 1 mg/ml drink in Belgium.
Johan Frödin, CEO of Unimedic Pharma says: "This marks a significant step for children with ADHD and insomnia. Our commitment to innovation and patient care drives us to develop solutions that address unmet medical needs, and we are very proud to offer this tre -
Unimedic Pharma AB announces distribution and launch of Zeqmelit® orodispersible film (dexametason) in Sweden, Norway, and Finland
Stockholm, September 17th, 2024 – Unimedic Pharma AB has according to plan started the distribution and launch of Zeqmelit® orodispersible film (dexametason) in Sweden, Norway, and Finland.
As Nordic partner to AcuCort, Unimedic Pharma carry the responsibility for marketing, distribution, and sales of the prescription drug Zeqmelit® (dexametason) in the Nordic region. From September, Zeqmelit® -
Unimedic Pharma AB out-license Melatonin oral solution in Belgium to TwinPharma BV
Unimedic Pharma AB has signed a distribution agreement with TwinPharma BV for the launch of Melatonin 1 mg/ml oral solution in Belgium.
Unimedic Pharma and TwinPharma entered into a supply and distribution agreement in 2017 and the addition of Melatonin 1mg/ml is the third product in the collaboration.
In this partnership, TwinPharma is appointed exclusive distributor of Melatonin Unimedi -
Unimedic Pharma AB announces new distribution agreement with AcuCort for Zeqmelit® oral film (dexametason) in Sweden, Denmark, Norway, and Finland
Stockholm, August 31st, 2023 – Unimedic Pharma AB announced today that Unimedic Pharma has entered into a license and distribution agreement with AcuCort AB for AcuCort’s Zeqmelit® oral film (dexametason) in Sweden, Denmark, Norway, and Finland.
-
Unimedic Pharma AB enter a collaboration with Consilient Health Limited for the launch of Melatonin oral solution in the UK
Unimedic Pharma AB have signed a license and supply agreement with Consilient Health for the launch of Melatonin 1 mg/ml oral solution in the UK. On November 16, 2021 the Medicines and Healthcare products Regulatory Agency (MHRA) granted Melatonin Consilient Health approval for insomnia in children with ADHD, as well as for short-term jet-lag therapy in adults
-
Melatonin Unimedic Pharma (lösning) erhåller subvention i Sverige och Norge
Melatonin Unimedic Pharma erhåller subvention i Sverige och Norge. Det är den första och enda registrerade orala beredningen innehållandes melatonin på dessa marknader som subventioneras för barn och ungdomar med adhd där sömnhygienåtgärder är otillräckliga.
-
Läkemedelsverket godkännner Mollisupradin, ett generiskt alternativ till Mollipect
Läkemedelsverket har idag meddelat att man godkänt Mollisupradin för behandling av hosta med segt slem och samtidigt behov av bronkvidgande effekt. Beslutet gäller från och med 8 maj 2020.
Kontakter
-
Johan Frödin Presskontakt CEO johan.frodin@unimedic.se +46 (0)70 878 72 80
